{"id":71366,"date":"2026-07-30T18:39:39","date_gmt":"2026-07-30T10:39:39","guid":{"rendered":"https:\/\/flcube.com\/?p=71366"},"modified":"2026-07-30T18:39:41","modified_gmt":"2026-07-30T10:39:41","slug":"akeso-and-allink-biotherapeutics-launch-phase-ii-trial-of-pd-1-vegf-fgfr2b-adc-combination-for-squamous-nsclc-following-nmpa-ind-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71366","title":{"rendered":"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Akeso, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9926:HKG\">HKG: 9926<\/a>) and <strong>Shanghai Allink Biotherapeutics Inc.<\/strong> announced a clinical research collaboration to advance a novel combination therapy for <strong>locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC)<\/strong>. China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>Investigational New Drug (IND) approval<\/strong> for the Phase II study evaluating <strong>Ivonescimab<\/strong> (PD-1\/VEGF bispecific antibody) in combination with <strong>ALK201<\/strong> (FGFR2b-targeted antibody-drug conjugate) as first-line treatment.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agencies<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND approval for Phase II clinical trial<\/td><\/tr><tr><td><strong>Combination Therapy<\/strong><\/td><td>Ivonescimab + ALK201<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line treatment of locally advanced or metastatic sqNSCLC<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>Allink Biotherapeutics (full responsibility for execution)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ivonescimab (AK112):<\/strong> Globally <strong>first-in-class PD-1\/VEGF bispecific antibody<\/strong> developed by Akeso, simultaneously blocking immune checkpoint inhibition and angiogenesis pathways<\/li>\n\n\n\n<li><strong>ALK201:<\/strong> <strong>FGFR2b-targeted antibody-drug conjugate (ADC)<\/strong> developed by Allink Biotherapeutics, delivering cytotoxic payload specifically to FGFR2b-expressing tumor cells<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First combination of a <strong>PD-1\/VEGF bispecific antibody<\/strong> with an <strong>FGFR2b-targeted ADC<\/strong>, designed to overcome treatment resistance through dual complementary mechanisms<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Global patents held by respective companies covering molecular structures and combination methodology<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-rationale-amp-unmet-need\" class=\"wp-block-heading\">Clinical Rationale &amp; Unmet Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Squamous NSCLC represents approximately 25-30% of all NSCLC cases and remains challenging to treat, particularly in patients without actionable driver mutations. Current first-line options are limited primarily to immunotherapy combinations with modest survival benefits. The <strong>dual-target approach<\/strong> combines:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Immune-oncology enhancement<\/strong> through PD-1 blockade<\/li>\n\n\n\n<li><strong>Anti-angiogenic effects<\/strong> via VEGF inhibition<\/li>\n\n\n\n<li><strong>Targeted cytotoxic delivery<\/strong> through FGFR2b-specific ADC<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">This multi-pronged strategy aims to improve response rates and duration while potentially overcoming primary and acquired resistance mechanisms commonly observed with single-agent approaches.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Akeso:<\/strong> Expands Ivonescimab&#8217;s clinical development beyond existing monotherapy and combination programs, creating additional partnership opportunities<\/li>\n\n\n\n<li><strong>For Allink Biotherapeutics:<\/strong> Validates FGFR2b as a viable target in sqNSCLC and accelerates ALK201 development through strategic alliance with established biopharmaceutical company<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses significant unmet need in ~200,000 annual sqNSCLC cases in China alone, with potential global applicability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps\" class=\"wp-block-heading\">Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Initiation:<\/strong> Patient enrollment expected to commence within Q3 2026<\/li>\n\n\n\n<li><strong>Primary Endpoints:<\/strong> Safety, tolerability, objective response rate (ORR), and progression-free survival (PFS)<\/li>\n\n\n\n<li><strong>Geographic Scope:<\/strong> Initial focus on Chinese sites with potential expansion to international locations based on early data<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and strategic partnerships. Actual results may differ due to risks including trial execution challenges, safety findings, and competitive dynamics in the oncology space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,360,2446,16,62,18],"class_list":["post-71366","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-akeso-biopharma","tag-allink-biotherapeutics","tag-cancer","tag-clinical-trial-approval-initiation","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to advance a novel combination therapy for locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). China&#039;s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for the Phase II study evaluating Ivonescimab (PD-1\/VEGF bispecific antibody) in combination with ALK201 (FGFR2b-targeted antibody-drug conjugate) as first-line treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71366\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval\" \/>\n<meta property=\"og:description\" content=\"Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to advance a novel combination therapy for locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). China&#039;s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for the Phase II study evaluating Ivonescimab (PD-1\/VEGF bispecific antibody) in combination with ALK201 (FGFR2b-targeted antibody-drug conjugate) as first-line treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71366\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T10:39:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T10:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71366#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71366\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\\\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval\",\"datePublished\":\"2026-07-30T10:39:39+00:00\",\"dateModified\":\"2026-07-30T10:39:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71366\"},\"wordCount\":431,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Akeso Biopharma\",\"Allink Biotherapeutics\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71366#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71366\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71366\",\"name\":\"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\\\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-30T10:39:39+00:00\",\"dateModified\":\"2026-07-30T10:39:41+00:00\",\"description\":\"Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to advance a novel combination therapy for locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). China's National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for the Phase II study evaluating Ivonescimab (PD-1\\\/VEGF bispecific antibody) in combination with ALK201 (FGFR2b-targeted antibody-drug conjugate) as first-line treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71366#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71366\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71366#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\\\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to advance a novel combination therapy for locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). China's National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for the Phase II study evaluating Ivonescimab (PD-1\/VEGF bispecific antibody) in combination with ALK201 (FGFR2b-targeted antibody-drug conjugate) as first-line treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71366","og_locale":"en_US","og_type":"article","og_title":"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval","og_description":"Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to advance a novel combination therapy for locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). China's National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for the Phase II study evaluating Ivonescimab (PD-1\/VEGF bispecific antibody) in combination with ALK201 (FGFR2b-targeted antibody-drug conjugate) as first-line treatment.","og_url":"https:\/\/flcube.com\/?p=71366","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-30T10:39:39+00:00","article_modified_time":"2026-07-30T10:39:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71366#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71366"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval","datePublished":"2026-07-30T10:39:39+00:00","dateModified":"2026-07-30T10:39:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71366"},"wordCount":431,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Akeso Biopharma","Allink Biotherapeutics","Cancer","Clinical trial approval \/ initiation","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71366#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71366","url":"https:\/\/flcube.com\/?p=71366","name":"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-30T10:39:39+00:00","dateModified":"2026-07-30T10:39:41+00:00","description":"Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to advance a novel combination therapy for locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). China's National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) approval for the Phase II study evaluating Ivonescimab (PD-1\/VEGF bispecific antibody) in combination with ALK201 (FGFR2b-targeted antibody-drug conjugate) as first-line treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71366#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71366"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71366#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1\/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71366"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71366\/revisions"}],"predecessor-version":[{"id":71378,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71366\/revisions\/71378"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}